Lead sponsor
UCB Biopharma SRL
3 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
3
Trials led
1
Ongoing
510
Total enrollment
127
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
2
Phase 2
1
Trials by status
Active, not recruiting
1
Completed
2
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)mild AD dementiaPh 2Completed466
A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)Study partner/caregiver requiredPh 1Completed25
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear PalsyAge ≥40Ph 1Active, not recruiting19